Mode
Text Size
Log in / Sign up

Swiss IgAN cohort shows 43% ESKD progression, high immunosuppressive use over 8-year follow-upWhat happens to IgA nephropathy patients over time? A Swiss study followed 158 people

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note: In a Swiss IgAN cohort, 43% progressed to ESKD; immunosuppressive use was common but linked to severe presentation.

A retrospective cohort analysis examined 158 adult patients with biopsy-proven immunoglobulin A nephropathy (IgAN) diagnosed between 1980 and 2016 at a Swiss tertiary center. At diagnosis, mean eGFR was 55.7 ml/min/1.73 m², mean proteinuria was 2.4 g/d, and 69.9% were hypertensive. Initial biopsy showed moderate to severe interstitial fibrosis and tubular atrophy (IFTA) in 29.1% and crescents in 36.7%. Treatment included renin-angiotensin-aldosterone system inhibitors in 86.7% and immunosuppressive therapy (steroids and other agents, mainly azathioprine) in 46.8% of patients.

Over a median follow-up of 100.0 months, 43.0% of patients progressed to end-stage kidney disease (ESKD). Complete remission occurred in 34.1%, partial remission in 22.2%, and relapses in 32.0%. Among patients who received a kidney transplant, recurrence occurred in 18.8%. Immunosuppressive therapy was used more frequently in patients presenting with higher proteinuria, higher hematuria grade, lower eGFR, more intense IgA and complement C3 staining, and crescents.

Predictors of progression to ESKD included higher age, lower eGFR, higher proteinuria and blood pressure, presence of crescents, and greater extent of IFTA on the initial biopsy. Safety and tolerability data for treatments were not reported. The study's key limitation is its retrospective, single-center design, which limits generalizability and establishes associations rather than causation.

This analysis provides insight into the characteristics, outcomes, and treatment practices for IgAN patients at a Swiss tertiary center over several decades. The high rate of ESKD progression observed underscores the serious prognosis of this condition. The findings regarding predictors of progression and patterns of immunosuppressive use may inform clinical assessment, but causal treatment effects cannot be inferred from this observational data.

IgA nephropathy is a kidney disease where the body's immune system mistakenly attacks the kidneys. A new look back at medical records from a Swiss hospital followed 158 adults diagnosed with this condition for a median of about 8 years. The findings paint a sobering picture: 43% of these patients progressed to end-stage kidney disease, meaning their kidneys failed and they needed dialysis or a transplant. Nearly half of the patients (46.8%) were treated with immunosuppressive drugs like steroids, which were used more often in people with more severe symptoms at diagnosis.

The study also identified factors linked to a higher risk of the disease getting worse. These included being older, having lower kidney function, higher levels of protein in the urine, higher blood pressure, and certain signs of damage seen on the initial kidney biopsy.

It's crucial to understand what this study is and isn't. It's a retrospective look at past patient charts from one hospital, which means it can show associations but cannot prove what caused the outcomes. The high rate of kidney failure reflects the experience of patients at this specific tertiary center over several decades and may not represent what happens everywhere. The study doesn't report on the safety or side effects of the treatments used.

What this means for you:
In a Swiss study, 43% of IgA nephropathy patients progressed to kidney failure over 8 years.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
IntroductionImmunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Geographic differences in disease course and treatment response are well recognized. The purpose of this analysis was to study clinical and histological characteristics, treatment practices and outcome of IgAN cases from a Swiss tertiary center.MethodsThis retrospective cohort analysis identified 158 cases of adult biopsy-proven IgAN by chart review diagnosed between 1980 and 2016. Following detailed phenotyping, standard descriptive methods and univariate analysis were applied.ResultsThe majority of patients was male and of European ancestry. At diagnosis, mean estimated glomerular filtration rate (eGFR) was 55.7 ml/min/1.73 m2, mean proteinuria was 2.4 g/d and 69.9% of the patients were hypertensive. Clinical presentation varied according to age. Initial biopsies showed moderate to severe tubular atrophy and interstitial fibrosis (IFTA) in 29.1% and crescents in 36.7% of cases. Therapy included renin-angiotensin-aldosterone-inhibitors in 86.7% as well as immunosuppressive therapy in 46.8% including steroids and other immunosuppressive drugs (28.7%), mainly azathioprin. Outcome included 34.1% complete and 22.2% partial remissions, relapses in 32.0% of patients, while 43.0% of patients progressed to ESKD during follow-up (median 100.0 months). Recurrence rate after transplantation was 18.8%. Immunosuppressive therapy was more frequently used in patients with higher proteinuria level, higher hematuria grade, lower eGFR, more intense IgA and complement C3 staining and crescents. Predictors of progression were higher age, lower eGFR, higher proteinuria and blood pressure as well as crescents and higher extent of IFTA on the initial biopsy.ConclusionsThis retrospective cohort analysis gives insight into characteristics and outcome of patients with IgAN from a Swiss tertiary center, treatment practices as well as predictors of outcome and therapy choices. A comparatively high use of immunosuppressive treatment including non-steroid-based regimens was found along with a high rate of progression to ESKD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.